Dognosis reports strong validation results for dog-assisted cancer breath test
Bengaluru-based Dognosis tested its non-invasive cancer-screening method across six Karnataka hospitals, reporting 90.8% sensitivity and 91.3% specificity among more than 1,500 participants. The validation puts it alongside consumer-facing early-detection players such as Nura and Cent.
What happened
Bengaluru startup Dognosis validated a dog-assisted breath test for cancer screening across six Karnataka hospitals. The company reported 90.8% sensitivity and
Key facts
- 90.8% sensitivity
- 91.3% specificity
- over 1,500 participants
- six Karnataka hospitals
- March 2024 to June 2025
What changed
Bengaluru startup Dognosis validated a dog-assisted breath test for cancer screening across six Karnataka hospitals. The company reported 90.8% sensitivity and 91.3% specificity, positioning its non-invasive test against D2C full-body scan providers Nura and Cent.
Why this matters
Reported 90.8% sensitivity and 91.3% specificity across more than 1,500 participants meaningfully de-risk Dognosis’s concept, though regulatory clearance, larger studies, and commercialization economics remain critical next tests.
What to watch
- Peer-reviewed publication or disclosure of performance by cancer type and early-stage disease.
- Indian regulatory authorization, clinical-guideline inclusion or hospital procurement approvals.
- Independent replication by institutions outside the original Karnataka hospital network.
- Pilot partnerships with national diagnostic chains, insurers, pharmacy retailers or large employers.
- Reported positive-screen referral completion rates, diagnostic yield and false-positive management costs.